Hypothyroidism is widely acknowledged as the most common immune-related endocrine toxicity, which occurs in approximately 30%–40% of anti-PD-1/PD-L1-treated patients (Larkin et al., 2019; Wright et al., 2021). This evidence concerns the gene PDCD1 and hypothyroidism.